oAlert.pl

Recalled Medicines & supplements – Current GIS Alerts 2026

Found 698 recalled products in the Medicines & supplements category. Check batch numbers, shops, and hazard information.

Common hazards in this category

All recalled products

Benodil – recalled product

Benodil

HIGH 17.11.2023

Failure to meet quality requirements consists in ampoules being labeled as a different medicinal product with a higher strength, which may cause dosing mix‑ups and medication errors. Potential effects: lack of treatment efficacy or complications related to incorrect dosing.

BOSS Energy, Dietary supplement – recalled product

BOSS Energy, Dietary supplement

HIGH 17.11.2023

Presence of undeclared pharmacologically active substances: sildenafil and tadalafil. Unknown origin, purity and dosage. Potential effects: drug interactions, blood pressure drop, arrhythmias, serious reactions in people taking PDE5 inhibitors or nitrates.

Linezolid Polpharma – recalled product

Linezolid Polpharma

MEDIUM 17.11.2023

Stability testing showed non-compliance in active substance release after 30 minutes, which may affect the product’s effectiveness and poses a real risk to patient health due to potential lack of efficacy. Potential effects: treatment failure, risk of infection progression.

Benodil – recalled product

Benodil

HIGH 10.11.2023

there is a justified suspicion that the unit packs of the medicinal product contain a product with a significantly higher dose of active substance than indicated on the outer labelling, creating a real risk that patients will take several times the intended dose. Potential effects: overdose of inhaled medicine, increased corticosteroid side effects, complications in sensitive patients.

Temozolomide Sun – recalled product

Temozolomide Sun

MEDIUM 09.11.2023

The active substance content is reduced below the lower acceptable limit specified in the product specification, which affects the medicinal product’s effectiveness. Potential effects: lack of treatment efficacy.

Temozolomide Sun – recalled product

Temozolomide Sun

MEDIUM 09.11.2023

Stability testing showed that the product does not meet quality specification requirements for active substance content; the content is reduced below the lower acceptance limit, which affects the product’s effectiveness. Potential effects: reduced treatment efficacy, possible lack of therapeutic effect.

BOSS Energy Extra, Food supplement – recalled product

BOSS Energy Extra, Food supplement

HIGH 30.10.2023

Detected sildenafil, a medicinal substance prohibited in dietary supplements; consumption may pose health risks. Potential effects: cardiovascular disturbances, drug interactions (e.g. nitrates), complications in people with heart conditions.

Mebelin – recalled product

Mebelin

MEDIUM 30.10.2023

Testing by the National Medicines Institute showed that the product does not meet quality requirements: release of mebeverine hydrochloride after 2, 8 and 12 hours was below the lower acceptance limit, which affects the effectiveness of the medicine. Potential effects: reduced effectiveness in treating intestinal complaints and possible worsening of disease symptoms.

Mebelin – recalled product

Mebelin

MEDIUM 30.10.2023

Tests by the National Medicines Institute showed that the product does not meet the quality specification for mebeverine hydrochloride release – release after 2, 8 and 12 hours was below the lower acceptance limit, affecting the product’s effectiveness. Potential effects: lack or reduction of therapeutic efficacy, possible worsening of disease symptoms.

White Horse – dietary supplement – recalled product

White Horse – dietary supplement

HIGH 26.10.2023

Detected sildenafil — an undeclared pharmacologically active substance in the product. Potential effects: drug interactions, cardiovascular disturbances, poisoning.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Keeping a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of the actual composition of the falsified product or its impact on pharmacological, immunological or metabolic action. Potential effects: poisoning, lack of treatment efficacy, severe complications.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; there is no confirmation of its actual composition or its effect on the medicine’s action. Potential effects: poisoning, lack of treatment efficacy, severe complications, life-threatening events.

Symibace – recalled product

Symibace

CRITICAL 20.10.2023

Stability studies showed a significant exceedance of the specification limit for impurity B, which poses a real and direct risk to patients’ health or life until the cause of the non-compliance is clarified. Potential effects: poisoning, serious adverse reactions, life-threatening events.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially to life. There is no confirmation of the actual composition or of the pharmacological, immunological or metabolic action of this product. Potential effects: poisoning, lack of treatment efficacy, severe complications, unpredictable reactions.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Leaving a falsified medicinal product on the market poses a direct and real threat to patients’ health and potentially life; the unknown composition and pharmacological action make its impact on the patient unpredictable. Potential effects: poisoning, lack of treatment efficacy, severe complications.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

The falsified medicinal product with unknown composition poses a direct and real threat to health and potentially also to patients’ lives; its pharmacological, immunological or metabolic effects cannot be predicted. Potential effects: poisoning, lack of therapeutic efficacy, severe complications, allergic reactions or other unpredictable adverse effects.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Keeping the falsified medicinal product on the market poses a direct threat to patients’ health and potentially life, because there is no confirmation of the actual composition of the medicine and its impact on pharmacological, immunological or metabolic action cannot be predicted. Potential effects: poisoning, lack of efficacy, severe complications.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Keeping a falsified medicinal product on the market poses a direct and real threat to health and potentially also to patients’ lives; the lack of confirmed composition makes it impossible to predict its effect on pharmacological action and treatment safety. Potential effects: poisoning, lack of treatment efficacy, serious adverse reactions.

Symibace – recalled product

Symibace

CRITICAL 20.10.2023

Stability studies showed a significantly exceeded content of impurity B; the authority indicated that any exceedance of specification limits constitutes a real and direct threat to patients’ health or life. Potential effects: poisoning, serious adverse reactions, life-threatening events.

Ozempic – recalled product

Ozempic

CRITICAL 20.10.2023

Keeping on the market a medicinal product for which falsification has been confirmed poses a direct and real threat to patients’ health and potentially life; there is no confirmation of the actual composition of the falsified product or its impact on the medicine’s effect. Potencjalne skutki: poisoning, lack of treatment efficacy, unpredictable adverse reactions.

What to do if you bought a recalled product?

If you have purchased any of the products listed above, stop using or consuming them immediately. You can return the product to the store where you bought it for a full refund. Keep the receipt if possible, but most stores will accept returns even without one.